The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna Therapeutics.
Source link : https://www.washingtonpost.com/business/2024/09/26/fda-antipsychotic-mental-illness-alzheimers/
Author : Daniel Gilbert
Publish date : 2024-09-26 23:10:36
Copyright for syndicated content belongs to the linked Source.
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
